294 related articles for article (PubMed ID: 32657929)
1. Patient-derived Organoid Pharmacotyping is a Clinically Tractable Strategy for Precision Medicine in Pancreatic Cancer.
Seppälä TT; Zimmerman JW; Sereni E; Plenker D; Suri R; Rozich N; Blair A; Thomas DL; Teinor J; Javed A; Patel H; Cameron JL; Burns WR; He J; Tuveson DA; Jaffee EM; Eshleman J; Szabolcs A; Ryan DP; Ting DT; Wolfgang CL; Burkhart RA
Ann Surg; 2020 Sep; 272(3):427-435. PubMed ID: 32657929
[TBL] [Abstract][Full Text] [Related]
2. Precision Medicine in Pancreatic Cancer: Patient-Derived Organoid Pharmacotyping Is a Predictive Biomarker of Clinical Treatment Response.
Seppälä TT; Zimmerman JW; Suri R; Zlomke H; Ivey GD; Szabolcs A; Shubert CR; Cameron JL; Burns WR; Lafaro KJ; He J; Wolfgang CL; Zou YS; Zheng L; Tuveson DA; Eshlemann JR; Ryan DP; Kimmelman AC; Hong TS; Ting DT; Jaffee EM; Burkhart RA
Clin Cancer Res; 2022 Aug; 28(15):3296-3307. PubMed ID: 35363262
[TBL] [Abstract][Full Text] [Related]
3. Patient-Derived Organoid Pharmacotyping Guides Precision Medicine for Pancreatic Cancer.
Zhang Y; Houchen CW; Li M
Clin Cancer Res; 2022 Aug; 28(15):3176-3178. PubMed ID: 35617521
[TBL] [Abstract][Full Text] [Related]
4. Development of Patient-Derived Gastric Cancer Organoids from Endoscopic Biopsies and Surgical Tissues.
Gao M; Lin M; Rao M; Thompson H; Hirai K; Choi M; Georgakis GV; Sasson AR; Bucobo JC; Tzimas D; D'Souza LS; Buscaglia JM; Davis J; Shroyer KR; Li J; Powers S; Kim J
Ann Surg Oncol; 2018 Sep; 25(9):2767-2775. PubMed ID: 30003451
[TBL] [Abstract][Full Text] [Related]
5. Patient derived organoids in prostate cancer: improving therapeutic efficacy in precision medicine.
Pamarthy S; Sabaawy HE
Mol Cancer; 2021 Sep; 20(1):125. PubMed ID: 34587953
[TBL] [Abstract][Full Text] [Related]
6. Development of a Single-Cell Technique to Increase Yield and Use of Gastrointestinal Cancer Organoids for Personalized Medicine Application.
Gao M; Harper MM; Lin M; Qasem SA; Patel RA; Mardini SH; Gabr MM; Cavnar MJ; Pandalai PK; Kim J
J Am Coll Surg; 2021 Apr; 232(4):504-514. PubMed ID: 33253861
[TBL] [Abstract][Full Text] [Related]
7. Pancreatic cancer-derived organoids - a disease modeling tool to predict drug response.
Frappart PO; Walter K; Gout J; Beutel AK; Morawe M; Arnold F; Breunig M; Barth TF; Marienfeld R; Schulte L; Ettrich T; Hackert T; Svinarenko M; Rösler R; Wiese S; Wiese H; Perkhofer L; Müller M; Lechel A; Sainz B; Hermann PC; Seufferlein T; Kleger A
United European Gastroenterol J; 2020 Jun; 8(5):594-606. PubMed ID: 32213029
[TBL] [Abstract][Full Text] [Related]
8. Organoid Profiling Identifies Common Responders to Chemotherapy in Pancreatic Cancer.
Tiriac H; Belleau P; Engle DD; Plenker D; Deschênes A; Somerville TDD; Froeling FEM; Burkhart RA; Denroche RE; Jang GH; Miyabayashi K; Young CM; Patel H; Ma M; LaComb JF; Palmaira RLD; Javed AA; Huynh JC; Johnson M; Arora K; Robine N; Shah M; Sanghvi R; Goetz AB; Lowder CY; Martello L; Driehuis E; LeComte N; Askan G; Iacobuzio-Donahue CA; Clevers H; Wood LD; Hruban RH; Thompson E; Aguirre AJ; Wolpin BM; Sasson A; Kim J; Wu M; Bucobo JC; Allen P; Sejpal DV; Nealon W; Sullivan JD; Winter JM; Gimotty PA; Grem JL; DiMaio DJ; Buscaglia JM; Grandgenett PM; Brody JR; Hollingsworth MA; O'Kane GM; Notta F; Kim E; Crawford JM; Devoe C; Ocean A; Wolfgang CL; Yu KH; Li E; Vakoc CR; Hubert B; Fischer SE; Wilson JM; Moffitt R; Knox J; Krasnitz A; Gallinger S; Tuveson DA
Cancer Discov; 2018 Sep; 8(9):1112-1129. PubMed ID: 29853643
[TBL] [Abstract][Full Text] [Related]
9. Detecting drug resistance in pancreatic cancer organoids guides optimized chemotherapy treatment.
Hennig A; Baenke F; Klimova A; Drukewitz S; Jahnke B; Brückmann S; Secci R; Winter C; Schmäche T; Seidlitz T; Bereuter JP; Polster H; Eckhardt L; Schneider SA; Brückner S; Schmelz R; Babatz J; Kahlert C; Distler M; Hampe J; Reichert M; Zeißig S; Folprecht G; Weitz J; Aust D; Welsch T; Stange DE
J Pathol; 2022 Aug; 257(5):607-619. PubMed ID: 35373359
[TBL] [Abstract][Full Text] [Related]
10. Patient-derived organoid culture of gastric cancer for disease modeling and drug sensitivity testing.
Zu M; Hao X; Ning J; Zhou X; Gong Y; Lang Y; Xu W; Zhang J; Ding S
Biomed Pharmacother; 2023 Jul; 163():114751. PubMed ID: 37105073
[TBL] [Abstract][Full Text] [Related]
11. A Prospective Feasibility Trial to Challenge Patient-Derived Pancreatic Cancer Organoids in Predicting Treatment Response.
Beutel AK; Schütte L; Scheible J; Roger E; Müller M; Perkhofer L; Kestler AMTU; Kraus JM; Kestler HA; Barth TFE; Lemke J; Kornmann M; Ettrich TJ; Gout J; Seufferlein T; Kleger A
Cancers (Basel); 2021 May; 13(11):. PubMed ID: 34064221
[TBL] [Abstract][Full Text] [Related]
12. The impact of extracellular matrix on the precision medicine utility of pancreatic cancer patient-derived organoids.
Lumibao JC; Okhovat SR; Peck KL; Lin X; Lande K; Zou J; Engle DD
bioRxiv; 2023 May; ():. PubMed ID: 36747742
[TBL] [Abstract][Full Text] [Related]
13. The effect of extracellular matrix on the precision medicine utility of pancreatic cancer patient-derived organoids.
Lumibao JC; Okhovat SR; Peck KL; Lin X; Lande K; Yomtoubian S; Ng I; Tiriac H; Lowy AM; Zou J; Engle DD
JCI Insight; 2024 Jan; 9(1):. PubMed ID: 38051586
[TBL] [Abstract][Full Text] [Related]
14. Microfluidic Organoid Cultures Derived from Pancreatic Cancer Biopsies for Personalized Testing of Chemotherapy and Immunotherapy.
Choi D; Gonzalez-Suarez AM; Dumbrava MG; Medlyn M; de Hoyos-Vega JM; Cichocki F; Miller JS; Ding L; Zhu M; Stybayeva G; Gaspar-Maia A; Billadeau DD; Ma WW; Revzin A
Adv Sci (Weinh); 2024 Feb; 11(5):e2303088. PubMed ID: 38018486
[TBL] [Abstract][Full Text] [Related]
15. Testing Susceptibility of Patient-Derived Organoid Cultures to Therapies: Pharmacotyping.
Burkhart RA; Baker LA; Tiriac H
Methods Mol Biol; 2018; 1787():253-261. PubMed ID: 29736724
[TBL] [Abstract][Full Text] [Related]
16. Commentary on "Patient-derived Organoid Pharmacotyping is a Clinically Tractable Strategy for Precision Medicine in Pancreatic Cancer".
Merchant N
Ann Surg; 2020 Sep; 272(3):436-437. PubMed ID: 32694448
[No Abstract] [Full Text] [Related]
17. Establishment of organoid models for pancreatic ductal adenocarcinoma and screening of individualized therapy strategy.
Gong M; Meng H; Tan D; Li P; Qin J; An Q; Shi C; An J
Animal Model Exp Med; 2023 Oct; 6(5):409-418. PubMed ID: 37890865
[TBL] [Abstract][Full Text] [Related]
18. Implementing patient derived organoids in functional precision medicine for patients with advanced colorectal cancer.
Cartry J; Bedja S; Boilève A; Mathieu JRR; Gontran E; Annereau M; Job B; Mouawia A; Mathias P; De Baère T; Italiano A; Besse B; Sourrouille I; Gelli M; Bani MA; Dartigues P; Hollebecque A; Smolenschi C; Ducreux M; Malka D; Jaulin F
J Exp Clin Cancer Res; 2023 Oct; 42(1):281. PubMed ID: 37880806
[TBL] [Abstract][Full Text] [Related]
19. Ex vivo drug testing of patient-derived lung organoids to predict treatment responses for personalized medicine.
Taverna JA; Hung CN; Williams M; Williams R; Chen M; Kamali S; Sambandam V; Hsiang-Ling Chiu C; Osmulski PA; Gaczynska ME; DeArmond DT; Gaspard C; Mancini M; Kusi M; Pandya AN; Song L; Jin L; Schiavini P; Chen CL
Lung Cancer; 2024 Apr; 190():107533. PubMed ID: 38520909
[TBL] [Abstract][Full Text] [Related]
20. 3D imaging analysis on an organoid-based platform guides personalized treatment in pancreatic ductal adenocarcinoma.
Kang Y; Deng J; Ling J; Li X; Chiang YJ; Koay EJ; Wang H; Burks JK; Chiao PJ; Hurd MW; Bhutani MS; Lee JH; Weston BR; Maitra A; Ikoma N; Tzeng CD; Lee JE; DePinho RA; Wolff RA; Pant S; McAllister F; Katz MH; Fleming JB; Kim MP
J Clin Invest; 2022 Dec; 132(24):. PubMed ID: 36282600
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]